Ibogaine for Traumatic Brain Injury: What the Evidence Shows

Ibogaine produced significant improvements in veterans with traumatic brain injury in the 2023 Stanford study—documented at one month post-treatment across 30 special operations veterans. The proposed mechanism is biologically plausible. The evidence base is early, the study was not designed to test TBI outcomes specifically, and the people most likely to benefit are not the same as the people most likely to be harmed by the wrong programme.

This is not a post for people seeking an endorsement. It is a post for people who want an accurate account of what the evidence shows, what it cannot yet tell us, and who should proceed carefully.

What traumatic brain injury is — and why it is hard to treat

Traumatic brain injury occurs when an external force disrupts normal brain function. In the military context, blast exposure from improvised explosive devices is the predominant mechanism. The injury cascade that follows—axonal shearing, neuroinflammation, glutamate excitotoxicity, oxidative stress—can produce a constellation of lasting effects: impaired memory, reduced processing speed, attention dysregulation, executive function deficits, sleep disruption, and increased vulnerability to mood disorders.

TBI and PTSD co-occur at high rates in combat veterans. Studies estimate 15–22% of veterans who served in Iraq and Afghanistan experienced at least a mild TBI during deployment. Many of the same blast events that cause TBI also cause PTSD. The two conditions share overlapping symptoms and often reinforce each other—making both harder to treat than either alone.

Conventional treatment for TBI-related cognitive deficits is limited. Cognitive rehabilitation, sleep management, and symptom-specific medications address individual downstream effects but do not address the underlying neurological disruption. For veterans carrying both TBI and PTSD—a population that had largely cycled through conventional treatment before the Stanford study—the standard of care was producing inadequate results.

The CDC estimates 1.5 million Americans sustain TBI each year, with veterans representing a disproportionate share of severe and complex cases.

What the 2023 Stanford study found

The 2023 Stanford study published in Nature Medicine enrolled 30 special operations veterans who met criteria for PTSD, TBI, and treatment-resistant depression. These were not people who had never tried conventional treatment. They had. The evidence that conventional approaches were insufficient was built into the study’s inclusion criteria.

The primary findings at one month post-treatment:

• 88% average reduction in PTSD symptoms
• 87% average reduction in depression symptoms
• 81% average reduction in anxiety symptoms

Cognitive function was assessed alongside psychiatric outcomes. Participants demonstrated improvements on standardized cognitive measures—processing speed, attention, executive function—alongside the psychiatric symptom reductions. The study did not isolate TBI-specific outcomes as a primary endpoint, so the cognitive improvements cannot be cleanly attributed to TBI resolution rather than to reductions in PTSD and depression, which impair cognitive function independently. That distinction matters for how the findings are interpreted.

What the study does establish is that a population carrying both severe PTSD and TBI responded to ibogaine in a way that exceeded what conventional psychiatry had produced for them. The people who had already tried everything else, and who had the additional burden of neurological injury, produced the strongest documented ibogaine outcomes in any published study.

Special operations veterans are not a population that enters things naively. They have been through conventional treatment. They have been given diagnoses and medications. Many of them were sceptical that anything was going to work. The 88% PTSD reduction is striking not just because of the number, but because of who produced it—people who had already tried everything else and had documented neurological injury on top of psychiatric diagnoses.

The proposed mechanism: why ibogaine might address TBI

The neurological events ibogaine produces are well-characterized. Whether they address the specific pathophysiology of TBI is a question the current evidence can support with plausibility but not proof. Two mechanisms are particularly relevant.

GDNF upregulation. Ibogaine significantly increases the production of glial cell line-derived neurotrophic factor—a protein that supports neuronal survival, promotes the growth of new neural connections, and supports oligodendrocyte precursor cell survival. Oligodendrocytes are responsible for myelin production. TBI frequently involves demyelination—damage to the myelin sheaths that insulate axons and enable efficient neural signal transmission. An increase in GDNF production could theoretically support remyelination and neural repair in TBI-affected tissue. Research on ibogaine and GDNF has been ongoing for more than a decade. Noribogaine—the primary ibogaine metabolite—sustains elevated GDNF for weeks to months after a single administration, which may explain why effects appear durable at the one-month mark.

NMDA receptor antagonism. Part of the injury cascade in TBI involves excessive glutamate release, which overstimulates NMDA receptors and contributes to excitotoxic neuronal damage. Ibogaine acts as an NMDA receptor antagonist. In the context of acute TBI, this mechanism is relevant to the injury cascade itself; in the context of post-injury neurological dysfunction, the same mechanism may interrupt maladaptive neural patterns that have developed in the injured tissue.

These mechanisms are plausible. They are not proven in the context of TBI specifically. The clinical literature on ibogaine and TBI is currently limited to observational and open-label data—no randomized controlled trials have been completed with TBI endpoints as a primary outcome. The pharmacological rationale is solid. The clinical evidence requires more.

See how ibogaine works for a fuller account of the mechanism, including the GDNF and NMDA pathways.

What the evidence cannot yet tell us

The Stanford study is the most rigorous published data on ibogaine in a clinical population. It is also a study with genuine limitations that matter for how the findings are applied.

30 participants is not a definitive population. The numbers are compelling. They need replication in larger samples before they can be treated as established clinical outcomes. The consistency of the effect across participants is notable, but small sample sizes allow for the possibility that the population sampled was unusually responsive.

There was no placebo arm.This is a genuine methodological limitation. Without a control group, it is not possible to fully separate the effect of ibogaine from the effect of intensive clinical attention, the expectation of improvement, the disruption of routine, or the natural trajectory of these conditions over time. The magnitude of the reported reductions—88% in PTSD symptoms, compared to a 50% reduction considered a strong response in conventional antidepressant research—makes it unlikely that expectation alone explains the outcomes. But the absence of a placebo control is a real limitation, not a technicality.

Long-term outcomes are not yet established. The Stanford data documents outcomes at one month. What happens at six months, twelve months, and beyond requires follow-up data that is not yet published.

The TBI findings are secondary outcomes.The study enrolled participants who met TBI criteria but was designed to measure PTSD, depression, and anxiety as primary endpoints. The cognitive improvements observed are real data. They are not the same as a study designed specifically to test ibogaine’s effect on TBI-related cognitive deficits.

The Texas $50 million clinical trial programme—funded through UTMB, UTHealth Houston, Texas A&M University, and Baylor University—is expected to produce more rigorous data. It will likely include TBI endpoints and larger sample sizes. That data does not yet exist. Citing the Stanford numbers as proof that ibogaine treats TBI is not accurate. Citing them as a compelling signal that warrants urgent investigation is.

See the full account of the Stanford study for a detailed breakdown of the methodology, outcomes, and what the data can and cannot support.

Who Is Not Right for This

TBI does not override the medical contraindications that apply to everyone. In some cases, TBI-related comorbidities increase the contraindication risk.

• Anyone with QT prolongation or significant cardiac arrhythmia. This is an absolute contraindication. Ibogaine has real cardiac risk. It is not negotiable, and it does not change based on how severe the TBI is or how much the person wants to proceed. An EKG is required before any ceremony date is confirmed. Veterans with unaddressed cardiovascular disease from the physical demands of military service are not automatically cleared.
• Anyone currently taking SSRIs, SNRIs, or lithium.These are absolute contraindications regardless of whether the medications were prescribed for PTSD, depression, or TBI-related mood dysregulation. A physician-supervised taper is required before ceremony. This is not optional, and the taper timelines differ by medication—some require several weeks, others several months.
• Anyone in acute psychiatric crisis.TBI and PTSD together can produce states of acute instability. The medicine amplifies what is present. Entering ceremony in a state of acute crisis does not produce stabilization—it produces amplification. Someone who needs stabilization first is not an appropriate candidate for ceremony now.
• Anyone with active psychosis or schizophrenia spectrum disorder. TBI can, in rare cases, precipitate psychotic presentations. A thorough psychiatric history assessment is required before any ceremony.
• Anyone primarily seeking a cure. TBI is a structural injury. Ibogaine is not a repair kit. The evidence suggests meaningful functional improvements are possible. It does not suggest that all TBI sequelae resolve after a single ceremony. Someone whose expectation is a cure will encounter something other than what they hoped for.

The conversation that ends in “this is not the right path for you at this moment” happens regularly in intake. It is not a failure of the process. It is the process working correctly. See why ibogaine is not a cure for a fuller account of the expectation gap and who is not well-served by this work.

Is This Right for You?

Ibogaine ceremony at Transcend is available to candidates who meet the medical requirements and whose situation is appropriate for this work. Veterans with TBI and PTSD who have cycled through conventional treatment without adequate results are among the people the evidence suggests may respond strongly. They are not automatically appropriate candidates—the medical screening, cardiac assessment, psychiatric history, and medication review apply to everyone.

Ibogaine ceremony costs $2,000–$5,000 CAD and includes an on-site medical professional, cardiac monitoring, the medicine, facilitation, and a 2–3 day supervised recovery. Integration coaching is available separately at $150–$300 CAD per 60–90 minute session. The integration period after ceremony is not optional—it is when the neuroplasticity window opened by ibogaine is either used or wasted.

If you are a veteran with TBI and PTSD and want to understand whether this is appropriate for your specific situation, start with the FAQ, which covers contraindications and the screening process in detail. Applications are reviewed within 2–3 business days. The intake conversation reaches a clear conclusion. Start at the application form.

If you are still evaluating whether ibogaine ceremony makes sense for your situation, read the ceremony page first. It covers the full picture of what ceremony involves, what the recovery period requires, and what integration support is available.

Frequently asked questions